Victrex Upgrades FY Volume Guidance Amid Strong H1 Growth and Operational Challenges

The Glass Half Full (But Watch for Cracks)

Victrex’s H1 2025 results present a classic case of “yes, but…” – a story of robust volume growth tempered by operational growing pains. Let’s unpack what matters for investors.

By the Numbers: Volume vs Value

The headline figures reveal a tale of two metrics:

• 🎯 Volume Surge: 16% YoY growth to 2,018 tonnes – first 2,000+ tonne half since 2022
• 💰 ASP Squeeze: Average selling price down 10% to £72.3/kg (mix impact from booming VAR sales)
• 📉 Margin Erosion: Gross margin down 390bps to 44.1% (China ramp-up costs + FX punches)
• ⚖️ PBT Paradox: Underlying profit down 17% to £23.2m… but flat in constant currency

Where the Engine’s Purring

1. VARs Driving the Bus

Value-Added Resellers saw 30% volume growth – the unsung hero of H1. While lower-margin, this signals broader industrial demand picking up steam.

2. Medical’s Silver Linings

Despite flat revenues:

• Non-spine medical grew at 2023 peak levels
• CMF (cranio-maxillofacial) applications up 32%
• Pharma/non-implantable opportunities emerging

3. Cash is King

128% operating cash conversion (vs 64% in H1 2024) shows improved working capital management. Net debt down to £40.7m (£49.8m in 2024) despite £40m dividend payout.

Where the Wheels Squeak

1. China Growing Pains

The Panjin facility became the problem child:

• £4m PBT drag from operational teething issues
• FY25 volume guidance slashed from 100-200t to ~50t
• “Taskforce” deployed – corporate speak for “all hands on deck”

2. FX Headwinds Bite

Sterling’s strength created a £5m H1 profit hole. With 75-80% of exposure hedged, unhedged Asian currencies add volatility risk.

3. Medical’s Lumpy Recovery

Spine segment remains in the doldrums (25% of medical revs vs 39% in 2024). CEO’s “visibility remains low” translates to “don’t hold your breath”.

The Mega-Programme Moonshot

Victrex’s big bets:

• Magma: Petrobras contract signals scale-up from 2026
• PEEK Knee: First commercial launch expected in 2025
• Aerospace Composites: Qualification complete for LMPAEK™

My take: These remain “show me” stories – combined mega-programme revenue was just £10.2m in FY24.

Upgraded Guidance – With Caveats

Management now expects:

• High single-digit volume growth (up from mid-single)
• H2 PBT similar to H2 2024 (£28m)
• Gross margin 45-47% (down from ~50% guidance)

The rub? This assumes Medical recovery and China improvements materialise swiftly.

Investment Case: Constructive but Cautious

The Bullish Angle:

• Volume momentum across core markets
• Inventory down £12.3m YoY
• CAPEX falling post-investment phase (£8.6m vs £21.8m)

The Bearish Counter:

• ASP pressure likely persistent
• Medical turnaround = 2026 story?
• ROIC at 16% (5-yr avg) needs mega-programme boost

Final Thought – A Stock for the Patient

Victrex feels like coiled spring – if China operations click and Medical recovers, current 19x P/E could look cheap. But with management guiding to “a range of outcomes”, this remains a show-me story. Dividend hunters might appreciate the maintained payout, but growth investors will want to see H2 deliver on upgraded volume promises without further margin slips.

Key question for H2: Can they fix China’s teething issues before the market loses patience? The 12% inventory reduction shows operational discipline – now they need execution rigor.